Overview

Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-24
Target enrollment:
Participant gender:
Summary
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
Phase:
PHASE1
Details
Lead Sponsor:
Huons Co., Ltd.